SUPPLEMENTARY APPENDIX
This appendix has been provided by the authors to give readers additional information about their work. CI=Confidence Interval. a 95% confidence intervals of the difference in the subject incidence rates are calculated using the Newcombe-Wilson score method.
b Yes indicates non-inferiority criterion is met.
c *P values were calculated using Chi-Square test or Fisher's exact test when expected cell counts were < 5.
* Percentages are based on the number of subjects with data. * For this sensitivity analysis, a hepatic endpoint of interest is defined as any subject recording one of the two following results: ALT > 3x ULN, Total bilirubin > 2x ULN, without confirmation using a consecutive repeat test after at least 24 hours but within 1 week of original test. * For this sensitivity analysis, a renal event is defined as a serum creatinine increase of ≥ 1.5X the baseline value or the need for renal replacement therapy, without confirmation using a consecutive repeat test after at least 24 hours but within 1 week of original test. 
CI=Confidence Interval. a The upper bound of the two-sided 95% confidence interval was specified for testing the co-primary endpoints, comparing with the specified thresholds for hepatic and renal endpoints for the non-inferiority assessment. This gives a one-sided 2.5% Type I error for each of the hepatic and renal endpoints and was based on an application of the Bonferroni method to control the overall Type I error at 5%. Multiplicity adjustment was not applied to the two pairwise treatment group comparisons within each co-primary endpoint. This table displays a more conservative assessment using a two-sided 97.5% confidence interval, which further applies a post-hoc Bonferroni adjustment to the treatment group comparisons to achieve an individual one-sided 1.25% Type I error for each of the treatment group comparisons. b Yes indicates non-inferiority criterion is met.
c P values were calculated using Fisher's exact test.
Percentages are based on the number of subjects with data. A hepatic endpoint of interest is defined as any subject recording one of the two following results: ALT > 3x ULN, Total bilirubin > 2x ULN, confirmed by a consecutive repeat test after at least 24 hours but within 1 week of the original test. A renal event is defined as a serum creatinine increase of ≥ 1.5X the baseline value, confirmed by a repeat test after at least 24 hours but within 1 week, or the need for renal replacement therapy.
Table S3
Cholesterol The N's represent the percentage of patients that experienced an adverse event by treatment group. *If a patient experienced greater than one adverse event, the most severe was presented for severity of adverse event. Sample size and power were calculated based on the observed event rate in the placebo arm using the Pearson's chi-square test. For this power calculation both the treatment and placebo arms were standardized to 420 patients. 
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